Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00562575

Enrollment

Registered

2007-11-22

Start date

2007-05-31

Completion date

2008-02-29

Last updated

2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia

Brief summary

The purpose is to investigate the effect of oral doses of SLx-4090 over 14 days on subjects with high triglycerides.

Detailed description

1. Serum triglycerides 2. Serum lipids and lipoproteins 3. Safety and tolerability

Interventions

DRUGSLx-4090

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Male or female subjects with high triglyceride levels * Male or female subjects between age 18 and 65 years, inclusive

Exclusion criteria

* History of drug abuse * Any prescribed or over the counter medication taken within 2 weeks prior to administration of study drug or within 6 times the elimination half-life * Blood donation of more than 500ml blood in the previous 3 months * Any confirmed significant allergic reaction against any drug or multiple allergies

Design outcomes

Primary

Measure	Time frame
Serum triglycerides	14 days

Secondary

Measure	Time frame
Adverse events and vital signs	14 days

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026